Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients

Hepato-Gastroenterology

Volumn 58, Issue 112, 2011, Pages 1918-1925

  Halamkova, Jana ^a   Kiss, Igor ^a   Pavlovsky, Zdenek ^a   Jarkovsky, Jiri ^a   Tomasek, Jiri ^a   Tucek, Stepan ^a   Hanakova, Lada ^a   Moulis, Mojmir ^a   Cech, Zbynek ^b   Zavrelova, Jirina ^b   Penka, Miroslav ^b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Colorectal cancer; PAI 1; PAI 2; Plasminogen activator system; UPA; UPAR

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 2; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

ADULT; ADVANCED CANCER; ANGIOGENESIS; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHOTOMETRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84857672622     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10232     Document Type: Article

References (59)

1. Krueger S, Kalinski T, Wolf H, et al.: Interactions between human colon carcinoma cells, fibroblasts and monocytic cells in coculture-regulation of cathepsin B expression and invasiveness. Cancer Lett 2005; 223(2):313-322. (Pubitemid 40719629)
2. Greenberg SC, Orthner CL: Blood coagulation and fibrinolysis In: Lee GR, Foerster J, Lukens J, et al.: Wintrobe's Clinical Hematology, 10th edition, Wiliams & Wilkins, Baltimor; 1999:684-764.
3. De Bruin PA, Griffioen G, Verspaget HW, et al.: Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res 1987; 47(17):4654-4657. (Pubitemid 17124643)
4. Pyke C, Kristensen P, Ralfkiaer E, et al.: The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAIl is located in endothelial cells in tumor stroma. Cancer Res 1991; 51(15):4067-4071.
5. Fay WP, Shapiro AD, Shih JL, et al.: Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327(24):1729-1733.
6. Hill SA, Shaughnessy SG, Joshua P, et al.: Differential mechanisms targeting type 1 plasminogen activator inhibitor and vitronectin into the storage granules of a human megakaryocytic cell line. Blood 1996; 87(12):5061-5073. (Pubitemid 26189847)
7. Stefansson S, Peticlerc E, Wong MK, et al: inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2001; 276(11):8135-8141.
8. Sugiura Y, Ma L, Sun B, et al.: The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis. Cancer Res 1999; 59(6):1327-1336. (Pubitemid 29136266)
9. Mouquet F, Cuilleret F, Susen S, et al.: Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1. Eur Heart J 2009; 30(7):840-849.
10. Chazaud B, Ricoux R, Christov C, et al.: Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol 2002; 160(1):237-246. (Pubitemid 34052284)
11. Schmitt M, Wilhelm O, Reuning U, et al.: The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis & Proteolysis 2000; 14:114-132. (Pubitemid 30409285)
12. Baker EA, Bergin FG, Leaper DJ, et al.: Plasminogen activator system, vascular endothelial growth factor and colorectal cancer progression. J Clin Pathol 2000; 53(6):307-312.
13. Ganesh S, Sier CF, Heerding MM, et al.: Urokinase receptor and colorectal cancer survival. Lancet 1994; 344(8919):401-402. (Pubitemid 24248215)
14. Ploug M, Ronne E, Behrendt N, et al.: Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosylphosphatidylinositol. J Biol Chem 1991; 266(3):1926-1933. (Pubitemid 21908387)
15. Resnati M, Guttinger M, Valcamonica S, et al.: Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996; 15(7):1572-1582. (Pubitemid 26112379)
16. Busso N, Masur SK, Lazega D, et al.: Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epitelial cells. J Cell Biol 1994;126(1):259-270. (Pubitemid 24214945)
17. Nguyen DH, Hussaini IM, Gonias SL: Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 1998; 273(14):8502-8507. (Pubitemid 28168915)
18. Dumler I, Weis A, Mayboroda OA, et al.: The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem 1998; 273(1):315-321. (Pubitemid 28042211)
19. Durand MK, Bedker JS, Christensen A: Plasminogen activator inhibitor 1 and tumour growth, invasion and metastasis. Tromb Haemost 2004; 91(3):439-449.
20. Prager GW, Breuss JM, Steurer S, et al.: Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ Res 2004; 94(12):1562-1570. (Pubitemid 38856963)
21. Brückner A, Filderman AE, Kirchheimer JC, et al.: Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1. Cancer Res 1992; 52(11):3043-3047.
22. Kobayashi H, Moniva N, Gotoh J, et al.: Role of activated protein C in faciliting basement membrane invasion by tumor cells. Cancer Res 1994; 54(1):261-267. (Pubitemid 24042120)
23. Praus M, Collen D, Gerard RD: Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis. Int J Cancer 2002; 102(6):584-591. (Pubitemid 35334465)
24. Bajou K, Noël A, Gerard RD, et al.: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4(8):923-928.
25. Kanse SM, Kost C, Wilhelm OG, et al.: The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996; 224(2):344-353. (Pubitemid 26140568)
26. Nekarda H, Siewert JR, Schmitt M: Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 1994; 343(8889):117. (Pubitemid 24019365)
27. Zemzoum I, Kates RE, Ross JS, et al.: Invasion factors uPA/uPAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 2003; 21(6):1022-1028. (Pubitemid 46594130)
28. Sakakibara T, Hibi K, Koike M, et al.: Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer 2005; 93(7):99-803.
29. Ohba K, Miyata Y, Kanda S, et al.: Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. J Urol 2005; 174(2):461-465. (Pubitemid 40981574)
30. Pedersen H, Grendhal-Hansen J, Francis D, et al.: Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994; 54(1):120-123. (Pubitemid 24042098)
31. Konecny G, Untch M, Pihan A, et al.: Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 2001; 7(6):1743-1749. (Pubitemid 32708644)
32. Fujii T, Obara T, Tanno S, et al.: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. Hepato-gastroenterology 1999; 46(28):2299-2308. (Pubitemid 29454089)
33. Papadopoulou S, Scorilas A, Yotis J, et al.: Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas. Tumour Biol 2002; 23(3):170-178. (Pubitemid 44858308)
34. Waltz DA, Natkin LR, Fujita RM, et al.: Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin invest 1997; 100(1):58-67. (Pubitemid 27311243)
35. Grendahl-Hansen J, Christensen IJ, Rosenquist C, et al.: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53(11):2513-2521. (Pubitemid 23168015)
36. Knoop A, Andreasen PA, Andersen JA, et al.: Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998; 77(6):932-940. (Pubitemid 28101782)
37. Mulcahy HE, Duffy MJ, Gibbons D, et al.: Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994; 344(8922):583-584. (Pubitemid 24267218)
38. Ito H, Yonemura Y, Fujita H, et al.: Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor PAI 1 and PAI 2 in gastric cancer. Virchows Arch 1996; 427(5):487-496. (Pubitemid 126828180)
39. Bouchet C, Spyratos F, Martin PM, et al.: Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994; 69(2):398-405. (Pubitemid 24046572)
40. Foekens JA, Buessecker F, Peters HA, et al.: Plasminogen activator inhibitor 2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995; 55(7):1423-1427.
41. Maeda K, Chung YS, Sawada T, et al.: Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma. Int J Oncology 1996; 8:499-503. (Pubitemid 26082168)
42. Macaluso M, Montanari M, Marshall CM, et al.: Cytoplasmic and nuclear interaction between Rb family proteins and PAI-2: a physiological crosstalk in human corneal and conjunctival epithelial cells. Cell Death and Differ 2006; 13(9):1515-1522. (Pubitemid 44210354)
43. Darnell DA, Antalis TM, Johnstone RW, et al.: Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif. Mol Cell Biol 2003; 23(18):6520-6532. (Pubitemid 37075763)
44. Sumiyoshi K, Serizawa K, Urano T, et al.: Plasminogen activator system in human breast cancer. Int J Cancer 1992; 50:345-348.
45. Nagayama M, Sato A, Hayakawa H, et al.: Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer 1994; 73(5):1398-1405. (Pubitemid 24072545)
46. Smith R, Xue A, Gill A, et al.: High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma. World J Surg 2007; 31(3):493-502. (Pubitemid 46356075)
47. Nordengren J, Fredstorp Lidebring M, Bendahl PO, et al.: High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer. Int J Cancer 2002; 97(3):379-385. (Pubitemid 34049032)
48. Kammori M, Kaminishi M, Kobayashi K, et al.: Immunohistochemical analysis of PAI-2 (plasminogen activator inhibitor type 2) and p53 protein in early gastric cancer patients with recurrence: a preliminary report. Jpn J Clin Oncol 1999; 29(4):187-191. (In Japanese with English abstract)
49. Herszényi L, Farinati F, Cardin R, et al.: Tumor marker utility and prognostic relevance of cathepsln B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 2008; 10:194.
50. Angenete E, Langenskiöld M, Palmgren I, et al.: uPA and PAI-1 in rectal cancer-relationship to radiotherapy and clinical outcome. J Surg Res 2009; 153(1):46-53.
51. Nielsen HJ, Christensen IJ, Sørensen S, et al.: Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000; 7(8):617-623.
52. Rha SY, Yang WI, Gong SJ, et al.: Correlation of tissue and blood plasminogen activation system in breast cancer. Cancer Letters 2000; 150(2):137-145. (Pubitemid 30125847)
53. De Bruin PA, Verspaget, HW, Griffioen G, et al.: Plasminogen activator activity and composition in human colorectal carcinomas. Fibrinolysis 1987; 1:57-62. (Pubitemid 18066350)
54. Mulcahy HE, Duffy MJ, Gibbons D, et al.: Urokinase-type plasminogen activator and outcome in Dukes B colorectal cancer. Lancet 1994; 344:583-584. (Pubitemid 24267218)
55. Seetoo DQ, Crowe PJ, Russell PJ, et al.: Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 2003; 82(3):184-193. (Pubitemid 36278267)
56. Sato T, Nishimura G, Yonemura Y, et al.: Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology 1995; 52(4):347-352.
57. Langenskiöld M, Holmdahl L, Angenete E, et al.: Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer. Tumour Biol 2009; 30(4):210-20
58. Ganesh S, Sier CF, Heerding MM, et al.: Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Duke's stage B and C colorectal cancer. Br J Cancer 1997; 75(12):1793-1801. (Pubitemid 27230706)
59. Berger DH: Plasmin/plasminogen system in colorectal cancer. World J Surg 2002; 26(7):767-771.